| Walter Futterweit, "Endocrine therapy of transsexualism and potential complications of long-term treatment", Archives of Sexual Behavior, 27:2 May 1998, p. 209(18) |
| | Cross-sex hormonal treatment may have substantial medical side effects. |
| "Standards Of Care For Gender Identity Disorders", The Harry Benjamin Gender Dysphoria Association, January 1990 4.5.3 |
| 4.5.3: | The physician prescribing hormonal medication to a person for the purpose of effecting hormonal sex reassignment must warn the patient of possible negative complications which may arise and that physician should also make available to the patient (or refer the patient to a facility offering) monitoring of relevant blood chemistries and routine physical examinations including, but not limited to, the measurement of SGPT in persons receiving testosterone and the measurement of SGPT, bilirubin, triglycerides and fasting glucose in persons receiving estrogens. |
| Johannes Kemper, Dorette Polland, Kathrin Schiatterer, Gunter Stalla, Klaus Von Werder, Alexander Yassouridis, "A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients", Archives of Sexual Behavior, 27:5 October 1988, p. 475(18) |
| | Long-term follow-up studies of cross gender hormone treated transsexual patients have not been performed. |